By Josh White
Date: Thursday 23 Oct 2025
(Sharecast News) - Hutchmed China reported preclinical data on Thurdsay, showing strong anti-tumour activity for its novel cancer therapy HMPL-A251, the first investigational drug to emerge from the company's proprietary Antibody-Targeted Therapy Conjugate (ATTC) platform.
| Vesting of awards under Long Term Incentive Plan | 21-Oct-2025 | 09:30 | RNS |
| Appointment of Independent Non-executive Director | 14-Oct-2025 | 09:30 | RNS |
| Total Voting Rights | 30-Sep-2025 | 09:30 | RNS |
| Directorate Change | 26-Aug-2025 | 07:00 | RNS |
| 2025 Interim Results | 07-Aug-2025 | 12:00 | RNS |
| Chinese medicine firm employs Cambridge Universi... | 23-Dec-2009 | Guardian |
| Joint venture offers food for growth | 09-Oct-2009 | The Scotsman |
| Chi-Med unveils maiden profit | 31-Jul-2009 | The Scotsman |
| Chi-Med happy with drug tests | 14-Jul-2009 | The Scotsman |
| 'Watershed' year depends on US drugs trial says ... | 17-Mar-2009 | The Scotsman |
| Questor: Hutchison China Meditech | 03-Jul-2007 | Telegraph |
| The Week Ahead: Wolseley investors seek calm ami... | 19-Mar-2007 | The Independent |
| The Investment Column: Hutchison China MediTech | 21-Nov-2006 | The Independent |
| Shares That Sound Good | 02-Jun-2006 | Motley Fool UK |
No recent information was found.
| Currency | UK Pounds |
| Share Price | 227.00p |
| Change Today | -2.00p |
| % Change | -0.87 % |
| 52 Week High | 323.00p |
| 52 Week Low | 189.00p |
| Volume | 12,659 |
| Shares Issued | 872.15m |
| Market Cap | £1,979.78m |
| RiskGrade | 226 |
| Value |
|
|---|
| Price Trend |
|
|---|
| Income | ![]() |
|---|
| Growth |
|
|---|
| No dividends found |
| Time | Volume / Share Price |
| 16:29 | 104 @ 224.00p |
| 16:29 | 251 @ 224.00p |
| 15:29 | 2 @ 228.00p |
| 15:10 | 657 @ 227.16p |
| 13:39 | 2,000 @ 224.56p |
You are here: research